HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver.

AbstractBACKGROUND:
Several studies have implicated the mitogen-activated protein kinase (MAPK) signal pathway in non-hepatic organ ischemia-reperfusion injury. However, the role of p38 MAPK in hepatic ischemia-reperfusion injury remains unclear. This study investigated the role of p38 MAPK in hepatic ischemia-reperfusion injury.
METHODS:
Male Sprague-Dawley rats were divided into 4 groups (sham, FR-only, control, and FR-treated groups). The animals in the control and FR-treated groups were subjected to 30 minutes of warm ischemia with congestion of the gut. The FR-only and FR-treated groups received FR167653 (FR), which is a novel p38 MAPK inhibitor. The serum levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) were measured (each, n = 6). Liver tissue blood flow was measured at pre-ischemia, end-ischemia, and 30, 60, 90, and 120 minutes after reperfusion (each, n = 4). The liver tissues in the control and FR-treated groups were excised for p38 MAPK and c-Jun N-terminal kinase (JNK) analyses and histopathology (each, n = 4).
RESULTS:
Serum levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, TNF-alpha, and IL-1beta were significantly lower in the FR-treated group than in the control group, and liver tissue blood flow was significantly higher in the FR-treated group than in the control group. Histopathologically, tissue damage was milder in the FR-treated group than in the control group. Both p38 MAPK and JNK were markedly phosphorylated after 30 minutes of reperfusion, and FR inhibited the phosphorylation of p38 MAPK without affecting the JNK.
CONCLUSIONS:
FR decreased serum TNF-alpha and IL-1beta levels and liver injury associated with the inhibition of p38 MAPK activation. These results suggest that inhibiting the activation of p38 MAPK may attenuate warm ischemia-reperfusion injury of the liver.
AuthorsMitsunobu Kobayashi, Izumi Takeyoshi, Daisuke Yoshinari, Koshi Matsumoto, Yasuo Morishita
JournalSurgery (Surgery) Vol. 131 Issue 3 Pg. 344-9 (Mar 2002) ISSN: 0039-6060 [Print] United States
PMID11894041 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • FR 167653
  • Interleukin-1
  • Pyrazoles
  • Pyridines
  • Tumor Necrosis Factor-alpha
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
Topics
  • Animals
  • Enzyme Inhibitors (pharmacology)
  • Interleukin-1 (blood)
  • Ischemia (pathology, physiopathology)
  • Liver (drug effects, pathology)
  • Liver Circulation (drug effects)
  • Male
  • Mitogen-Activated Protein Kinases (antagonists & inhibitors, metabolism, physiology)
  • Phosphorylation (drug effects)
  • Pyrazoles (pharmacology)
  • Pyridines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury (pathology, physiopathology)
  • Tumor Necrosis Factor-alpha (analysis)
  • p38 Mitogen-Activated Protein Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: